Gallbladder Cancer Clinical Trial
Official title:
A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. immuno-histochemistry tests reveal the abnormal activation status of signal pathways involved in study.These information will be used to recommend target therapy which may be more likely to result in a beneficial response.Patients will receive target anti-tumor agents according to the result of genomic and proteomic profiling. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05237193 -
A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
|
||
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
| Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
| Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
| Withdrawn |
NCT00386516 -
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
|
Phase 2 | |
| Completed |
NCT00033540 -
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
|
Phase 2 | |
| Completed |
NCT00660699 -
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
|
Phase 2 | |
| Terminated |
NCT04066491 -
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Recruiting |
NCT05489250 -
The PLATON Network
|
||
| Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
| Completed |
NCT00753675 -
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT00304135 -
Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
|
Phase 2/Phase 3 | |
| Completed |
NCT00409864 -
Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer
|
N/A | |
| Completed |
NCT00084942 -
Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
|
Phase 2 | |
| Recruiting |
NCT04445532 -
Hepatobiliary Tumors Tissue Samples Acquisition
|
||
| Terminated |
NCT00658593 -
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
|
Phase 3 | |
| Completed |
NCT00486356 -
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06134193 -
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
|
Phase 2 |